This work was supported in part by grants from NHRI (CS-104-PP-06 to B.L.Y.).

Patient informed consent as approved by the institutional review board must be obtained for use of human cells.
1. Density Gradient Isolation of Human Peripheral Blood Mononuclear Cells (PBMCs)
<ol>
	<li>Add 25 ml heparinized whole blood into a 50 ml tube by a 25 ml pipette.
	<ol>
		<li>Dilute cells with 25 ml of phosphate-buffered saline (PBS).</li>
	</ol>
	</li>
	<li>Add 15 ml of Ficoll-Paque density gradient into a new 50 ml tube, and while tilting the tube, very slowly and carefully add in 25 ml of the diluted cell suspension over the density gradient so that there is no mixing of the whole blood with the density gradient, i.e., no disturbance of the blood-density gradient interface.</li>
	<li>Centrifuge the suspension from step 1.2 at 400 &#215; g for 30 to 40 min in a temperature-controlled swinging-bucket rotor without brake at 20 &#176;C. 
	Note: Three distinct layers should be apparent after centrifugation: the upper layer being plasma; the bottom clear layer being the Ficoll-Paque density gradient; and a thin, middle cellular layer being the PBMCs</li>
	<li>Aspirate and discard the upper layer by suction with a Pasteur pipette, with care not to disturb the interphase layer of mononuclear cells (i.e., lymphocytes, monocytes, and platelets).</li>
	<li>Carefully collect this mononuclear cell layer with a 10 ml pipette to a new 50 ml centrifuge tube.</li>
	<li>Fill the tube with 20 ml of PBS, mix well, and centrifuge at 300 &#215; g for 10 min at 20&#176;C. Remove the supernatant completely after centrifugation.</li>
	<li>Resuspend the cell pellet in 20&#160;ml of PBS and centrifuge at 200 &#215; g for 10-15 min at 20 &#176;C. Remove the supernatant completely after centrifugation. 
	Note: This step removes the platelets-which are unwanted-within the PBMCs; this step can be repeated to ensure complete removal of the platelets.</li>
	<li>If no selection of specific populations is desired, resuspend cell pellet in leukocyte complete medium (10% fetal bovine serum (FBS), 1% L-glutamine, and 1% penicillin/streptomycin in RPMI-1640 medium) for culturing after performing a cell count16 to suspend 1 ml of medium per 107 PBMCs before proceeding to the next step.</li>
</ol>
2. Magnetic Labeling of Leukocyte Populations (Skip to STEP 4 if no Selection of Specific Populations is Required)
<ol>
	<li>Centrifuge PBMC suspension at 300 &#215; g for 10 min and aspirate supernatant completely.</li>
	<li>Resuspend cell pellet in 80 &#181;l of PBS per 107 total cells.</li>
	<li>Add 20 &#181;l of specified magnetic beads (i.e., CD14 magnetic beads for isolation of monocytes, CD4 magnetic beads for isolation of T lymphocytes) per 107 total cells.</li>
	<li>Mix well and incubate for 15 min at 2 to 8 &#176;C in the refrigerator.</li>
	<li>Add 1-2 ml of PBS per 107 cells to wash, and centrifuge at 300 &#215; g for 10 min.</li>
	<li>Aspirate supernatant completely and resuspend up to 108 cells in 500 &#181;l of PBS.</li>
</ol>
3. Magnetic Selection of Leukocyte Subpopulations
Note: A variety of magnetic bead separators and columns are available for isolation of specific population of leukocytes by cell surface marker from a number of manufacturers. Isolation can be by positive selection based on one or a few positive markers or by negative selection after depletion of unwanted populations. A general approach of performing positive selection using one marker (i.e.,&#160;CD4 for T helper lymphocytes, or CD14 for monocytes) is outlined below.
<ol>
	<li>Prepare and prime magnetic separator including separation column according to manufacturer&#39;s instructions.</li>
	<li>Apply tube containing the sample of labeled PBMCs. Provide two 15 ml centrifuge tubes for collection of the positively labeled and unlabeled cell fractions, following manufacturer&#39;s instructions.</li>
	<li>Count cell number15 and resuspend the positively selected leukocytes (i.e.,&#160;CD4+ T lymphocytes or CD14+ cells) in leukocyte complete medium, using 1 ml of medium per 107 cells.</li>
</ol>
4. CFSE Staining of Leukocytes for Assessment of Proliferation
Note: CFSE has been widely used in immunological investigations, for both in vivo and in vitro studies. Our protocol has been optimized for in vitro study of MSC/PBMC (or other leukocyte) interactions. While the general steps involved in conducting CFSE in vitro labeling are similar, there may be differences in the specific dose and timing of the protocol14. This may be due to a number of factors, i.e., the specific cell type used, cell numbers used-which can likely affect the intensity of the CFSE fluorescent signal.
<ol>
	<li>Dilute the CFSE stock solution (10 mM) in PBS to the desired working concentration of 10 &#181;M (CFSE-working solution). Prepare 107 cells (i.e., PBMCs or T cells) for labeling with the CFSE-working solution.</li>
	<li>Centrifuge at 300 &#215; g for 10 min to obtain a cell pellet and aspirate the supernatant.</li>
	<li>Resuspend the cells gently in 1 ml of pre-warmed (37 &#176;C) CFSE-working solution and incubate the cells for 10 min at 37 &#176;C.</li>
	<li>To wash off excess CFSE, dilute the cell suspension with 10x (by volume) of precooled (4 &#176;C) RPMI medium containing 10% FBS. Sediment the cells by centrifugation at 300 x g for 5 min and discard the supernatant. Wash the cell pellet in this manner twice more.</li>
	<li>Re-pellet the cells by centrifugation and count cell number15. Resuspend 107 cells (either PBMCs or T cells) in 1 ml fresh prewarmed leukocyte complete medium.</li>
</ol>
5. Co-culture of MSCs with Leukocytes and Activation of Leukocytes
<ol>
	<li>Pre-warm MSC complete medium (10% FBS (pretested for optimal MSC growth), 1% L-glutamine, and 1% penicillin/streptomycin in DMEM-low glucose medium) to 37 &#176;C for no more than 30 min.</li>
	<li>Seed MSCs at 50,000 cells in 1&#160;ml of MSC complete medium in 24-well plates (MSC density: 25,000 cells/cm2) for attachment O/N in a 37 &#176;C incubator, allowing for the stem cells to reach 80% confluence.</li>
	<li>Aspirate medium, and based on seeded MSC numbers, add CFSE-labeled PBMCs (previously labeled-please refer to protocol Step 4 above) to cultured MSCs (seeded the previous day in 24-well plates) in 1&#160;ml of leukocyte complete medium at a 1:10 (cell ratio) co-culture ratio of MSCs to PBMCs.</li>
	<li>Add the mitogen phytohemagglutinin (PHA), a non-specific leukocyte activator, to a final concentration of 10 &#181;g/ml in a total volume of 1 ml leukocyte complete medium per well.
	<ol>
		<li>Alternatively, to stimulate for the activation of T lymphocytes specifically: use &#945;-CD3/28 microbeads and add to the two-cell co-culture to obtain a bead-to-T lymphocyte ratio of 1:1.</li>
	</ol>
	</li>
	<li>For negative control, plate 500,000 PBMCs/well (or a specific effector leukocyte population; cell density: 250,000 leukocytes/cm2) in a 24-well plate with 1 ml leukocyte complete medium only; for positive control, in addition to plating the same number of PBMCs/well, add PHA to a final concentration of 10 &#181;g/ml.</li>
	<li>On the 3rd and 5th day of the co-culture experiment, assess proliferation of CFSE-labeled leukocytes (placed in round-bottom tubes) by flow cytometric analysis17 with 488 nm excitation and emission filters appropriate for fluorescein. 
	Note: Intracellular cytokine staining for flow cytometric analysis can also be performed to these CFSE-labeled leukocytes at this point to assess for changes in leukocyte cytokine expression profile as modulated by MSCs. Since CFSE is evaluated with a filter appropriate for fluorescein, the antibodies selected to assess various cytokines need to be conjugated to fluorochromes other than fluorescein or similar spectrum (i.e., phycoerythrin, peridinin chlorophyll protein complex (PerCP)).</li>
</ol>
6. Variation: Effector Suppression Assay Magnetic Bead-selected, MSC-induced Immunomodulatory Leukocytes on Activated CFSE-labeled Effector CD4 + T Cells
<ol>
	<li>Seed MSCs at 250,000 cells in 3&#160;ml of MSC complete medium in 6-well plates (MSC density: 25,000 cells/cm2) for attachment O/N in a 37 &#176;C incubator, allowing for the stem cells to reach 80% confluence. &#160;At least 3 6-well plates are necessary to ensure enough MSC-cocultured PBMCs for subpopulation selection.&#160;</li>
	<li>Aspirate medium, and add PBMCs separated as per Step 1&#160;but in 6-well plates at 2.5 x 106 cells/well (cell density: 250,000 leukocytes/cm2) with 3 ml of leukocyte complete medium. Co-culture for 48-72 hr in a 37 &#176;C incubator.</li>
	<li>Magnetic bead-select specific population of MSC-induced immunomodulatory leukocytes (i.e., CD14+ cells) as per Sections 2-3. 
	Notes: Intracellular cytokine staining for flow cytometric analysis can be performed at this point to assess for changes in leukocyte cytokine expression profile, i.e.,&#160;expression of interleukin-10-as modulated by MSCs.</li>
	<li>Add CFSE-labeled allogeneic CD4+ T cells generated as per Sections 2-4 in 24-well plates in 1&#160;ml of leukocyte complete medium (T cell density: 250,000 cells/cm2) to bead-selected MSC-induced leukocytes at various ratios, i.e., 1:10, 1:5, 1:2, and 1:1 (cell to cell) ratios.</li>
	<li>To stimulate CD4+ T cells, add &#945;-CD3/28 conjugated microbeads to obtain a bead-to-cell ratio of 1:1.</li>
	<li>For a negative control, plate 500,000 CD4+ T cells/well in a 24-well plate (T cell density: 250,000 cells/cm2) with 1 ml leukocyte complete medium only; for positive control, in addition to plating the same number of CD4+ T cells/well, add &#945;-CD3/28 conjugated microbeads to obtain a bead-to-cell ratio of 1:1.</li>
	<li>On the 3rd day of co-culture, assess proliferation of CFSE-labeled CD4+ T cells (placed in round-bottom tubes) by flow cytometric analysis16 with 488 nm excitation and emission filters appropriate for fluorescein.</li>
</ol>

<ol>
	<li>Friedenstein, A. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Precursor+cells+of+mechanocytes.">Precursor cells of mechanocytes.</a> Int Rev Cytol. 47, 327-359 (1976).</li><li>Pittenger, M. F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Multilineage+potential+of+adult+human+mesenchymal+stem+cells.">Multilineage potential of adult human mesenchymal stem cells.</a> Science. 284, 143-147 (1999).</li><li>Prockop, D. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Marrow+stromal+cells+as+stem+cells+for+nonhematopoietic+tissues.">Marrow stromal cells as stem cells for nonhematopoietic tissues.</a> Science. 276, 71-74 (1997).</li><li>Dominici, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Minimal+criteria+for+defining+multipotent+mesenchymal+stromal+cells.+The+International+Society+for+Cellular+Therapy+position+statement.">Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.</a> Cytotherapy. 8, 315-317 (2006).</li><li>Engler, A. J., Sen, S., Sweeney, H. L., Discher, D. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Matrix+elasticity+directs+stem+cell+lineage+specification.">Matrix elasticity directs stem cell lineage specification.</a> Cell. 126, 677-689 (2006).</li><li>Zuk, P. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Multilineage+cells+from+human+adipose+tissue:+implications+for+cell-based+therapies.">Multilineage cells from human adipose tissue: implications for cell-based therapies.</a> Tissue Eng. 7, 211-228 (2001).</li><li>Yen, B. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Isolation+of+multipotent+cells+from+human+term+placenta.">Isolation of multipotent cells from human term placenta.</a> Stem Cells. 23, 3-9 (2005).</li><li>Erices, A., Conget, P., Minguell, J. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mesenchymal+progenitor+cells+in+human+umbilical+cord+blood.">Mesenchymal progenitor cells in human umbilical cord blood.</a> Br J Haematol. 109, 235-242 (2000).</li><li>Bartholomew, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mesenchymal+stem+cells+suppress+lymphocyte+proliferation+in+vitro+and+prolong+skin+graft+survival+in+vivo.">Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.</a> Exp Hematol. 30, 42-48 (2002).</li><li>Chang, C. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Placenta-derived+multipotent+cells+exhibit+immunosuppressive+properties+that+are+enhanced+in+the+presence+of+interferon-gamma.">Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma.</a> Stem Cells. 24, 2466-2477 (2006).</li><li>Uccelli, A., Moretta, L., Pistoia, V. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mesenchymal+stem+cells+in+health+and+disease.">Mesenchymal stem cells in health and disease.</a> Nat Rev Immunol. 8, 726-736 (2008).</li><li>Chen, P. M., Yen, M. L., Liu, K. J., Sytwu, H. K., Yen, B. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Immunomodulatory+properties+of+human+adult+and+fetal+multipotent+mesenchymal+stem+cells.">Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells.</a> J Biomed Sci. 18, 49-59 (2011).</li><li>Muul, L. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Measurement+of+proliferative+responses+of+cultured+lymphocytes.">Measurement of proliferative responses of cultured lymphocytes.</a> Curr Protoc Immunol. , (2011).</li><li>Quah, B. J., Warren, H. S., Parish, C. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Monitoring+lymphocyte+proliferation+in+vitro+and+in+vivo+with+the+intracellular+fluorescent+dye+carboxyfluorescein+diacetate+succinimidyl+ester.">Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester.</a> Nat Protoc. 2, 2049-2056 (2007).</li><li>Chen, P. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Induction+of+immunomodulatory+monocytes+by+human+mesenchymal+stem+cell-derived+hepatocyte+growth+factor+through+ERK1/2.">Induction of immunomodulatory monocytes by human mesenchymal stem cell-derived hepatocyte growth factor through ERK1/2.</a> J Leukoc Biol. 96, 295-303 (2014).</li><li>Oughton, J. A., Kerkvliet, N. I., Costa, L. G., Davila, J. C., Lawrence, D. A., Reed, D. J., Will, Y. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=UNIT+18.8+Immune+cell+phenotyping+using+flow+cytometry.">UNIT 18.8 Immune cell phenotyping using flow cytometry.</a> Curr Protoc Toxicol. , 18.8.1-18.8.24 (2005).</li><li>Phelan, M. C., Lawler, G., Robinson, J. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=APPENDIX+3A+Cell+counting.">APPENDIX 3A Cell counting.</a> Curr Protoc Cytom. , A.3A.1-A.3A.4 (2001).</li><li>Gebler, A., Zabel, O., Seliger, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+immunomodulatory+capacity+of+mesenchymal+stem+cells.">The immunomodulatory capacity of mesenchymal stem cells.</a> Trends Mol Med. 18, 128-134 (2012).</li><li>Le Blanc, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mesenchymal+stem+cells+for+treatment+of+steroid-resistant,+severe,+acute+graft-versus-host+disease:+a+phase+II+study.">Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.</a> Lancet. 371, 1579-1586 (2008).</li><li>Tan, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Induction+therapy+with+autologous+mesenchymal+stem+cells+in+living-related+kidney+transplants:+a+randomized+controlled+trial.">Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.</a> JAMA. 307, 1169-1177 (2012).</li><li>Le Blanc, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mesenchymal+stem+cells+inhibit+and+stimulate+mixed+lymphocyte+cultures+and+mitogenic+responses+independently+of+the+major+histocompatibility+complex.">Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex.</a> Scand J Immunol. 57, 11-20 (2003).</li><li>Li, X. Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Long-term+culture+in+vitro+impairs+the+immunosuppressive+activity+of+mesenchymal+stem+cells+on+T+cells.">Long-term culture in vitro impairs the immunosuppressive activity of mesenchymal stem cells on T cells.</a> Mol Med Rep. 6, 1183-1189 (2012).</li><li>Moll, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Do+cryopreserved+mesenchymal+stromal+cells+display+impaired+immunomodulatory+and+therapeutic+properties?.">Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?.</a> Stem Cells. 32, 2430-2442 (2012).</li><li>Ho, P. J., Yen, M. L., Tang, B. C., Chen, C. T., Yen, B. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=H2O2+accumulation+mediates+differentiation+capacity+alteration,+but+not+proliferative+decline,+in+senescent+human+fetal+mesenchymal+stem+cells.">H2O2 accumulation mediates differentiation capacity alteration, but not proliferative decline, in senescent human fetal mesenchymal stem cells.</a> Antioxid Redox Signal. 18, 1895-1905 (2013).</li></ol>

We have nothing to disclose.

Increasingly, the immunomodulatory properties of MSCs are being translated into clinical use more rapidly than the multilineage capacity of these stem cells18-20. Thus, co-culture techniques of MSCs with leukocytes and assays to evaluate immune function are important to further delineate the specific mechanisms involved in these properties for optimizing effective therapeutic application. 
One of the most critical technical aspects for success in these assays is having adequate PBMC...

Human mesenchymal stem cells (MSCs) are somatic progenitors that can differentiate into the paraxial mesodermal lineages of bone, cartilage, and adipose tissue1-4, as well as to a few extramesodermal lineages5. First isolated from the adult bone marrow, these multilineage progenitors have now been found in numerous tissues6-8 and, unexpectedly, shown to have strong immunomodulatory properties that appear highly amenable to clinical application9-12. Detailed mechanisms involved in the immunomodulatory effects are actively being investigated for effective application on specific disease entities. One of the most straightforward ways to evaluate immunomodulation is by assessing for the suppression of effector leukocyte proliferation13. Most effector leukocytes such as T lymphocytes and monocytes proliferate prodigiously when stimulated or activated. Immunomodulatory function can be assessed when suppression of proliferation is evidenced.
Traditionally, effector leukocyte proliferation has been evaluated by detection of [3H] thymidine incorporation into DNA. However, this method has significant drawbacks due to the concerns of radiation and post-use disposal, as well as the complex equipment needed. While there are non-radioactive assays to assess cell proliferation, the carboxyfluorescein succinimidyl ester (CFSE) assay has other advantages such as allowing for identification of specific cellular populations, which is especially useful in co-culture experiments involving multiple cell types. CFSE is a fluorescent cellular dye which can be assessed by flow cytometric analysis. As cells divide, the intensity of this cellular label is decreased proportionally; this not only enables determination of overall cell proliferation but also allows for the assessment on the number of cell divisions up to 8 divisions before the fluorescence becomes difficult to detect against background signal. Moreover, the stability of the fluorescent CFSE allows for in vivo tracking of labeled cells such that cells can be visualized up to many months14.
This assay can also be varied to evaluate specific types of effector leukocytes or the immunomodulatory function of specific populations of MSC-induced immunomodulatory leukocytes-such as interleukin-10 (IL-10) producing CD14+ monocytes15 by performing magnetic bead surface marker selection of cell populations of interest prior to or after co-culture as appropriate. Our protocol describes the basic assay of assessing the immunomodulatory effects of MSCs on effector leukocytes (flow chart shown in Figure 1) and a variation on this basic assay for evaluation of MSC-induced leukocyte immunomodulation on allogeneic CD4+ effector T lymphocytes (flow chart shown in Figure 4).

<table border="0" cellpadding="0" cellspacing="0" width="1205">
	<tbody>
		<tr height="20">
			<td height="20" style="height:20px;width:276px;">Ficoll-Paque PLUS</td>
			<td style="width:259px;">GE Healthcare</td>
			<td style="width:121px;">71-7167-00 AG</td>
			<td style="width:549px;">Density grandient for isolation of peripheral blood mononuclear cells (PBMCs)</td>
		</tr>
		<tr height="40">
			<td height="40" style="height:40px;width:276px;">Vibrant CFDA-SE Cell Tracer Kit (CFSE)</td>
			<td style="width:259px;">Life Technologies</td>
			<td style="width:121px;">V12883</td>
			<td>Cellular label for detection of cell division</td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;width:276px;">Phytoagglutinin (PHA)</td>
			<td style="width:259px;">Sigma</td>
			<td>L8902</td>
			<td>Activation of human PBMCs</td>
		</tr>
		<tr height="40">
			<td height="40" style="height:40px;width:276px;">Dynabeads Human T-Activator CD3/28</td>
			<td style="width:259px;">Life Technologies</td>
			<td style="width:121px;">111.32D</td>
			<td style="width:549px;">Activation of human T lymphocytes, e.g. CD4+ T cells, CD8+ T cells,etc.</td>
		</tr>
		<tr height="40">
			<td height="40" style="height:40px;">autoMACS&#8482; Separator</td>
			<td>Miltenyi Biotec</td>
			<td style="width:121px;">autoMACS&#8482; Separator</td>
			<td>Magnetic based cell separator</td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">autoMACS&#174; Columns</td>
			<td>Miltenyi Biotec</td>
			<td>130-021-101</td>
			<td>separation columns</td>
		</tr>
		<tr height="25">
			<td height="25" style="height:25px;width:276px;">CD14 microbeads, human&#160;</td>
			<td>Miltenyi Biotec</td>
			<td>130-050-201</td>
			<td style="width:549px;">For positive selection of CD14+ human monocytes and macrophages from PBMCs</td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;width:276px;">CD4 microbeads, human&#160;</td>
			<td>Miltenyi Biotec</td>
			<td style="width:121px;">130-045-101</td>
			<td style="width:549px;">For positive selection of CD4+ human T lymphocytes from PBMCs</td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;width:276px;">RPMI 1640 Medium</td>
			<td style="width:259px;">Life Technologies</td>
			<td style="width:121px;">11875</td>
			<td>Human PBMC/leukocyte culture medium</td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;width:276px;">DMEM, Low glucose, pyruvate</td>
			<td style="width:259px;">Life Technologies</td>
			<td style="width:121px;">11885</td>
			<td style="width:549px;">Human mesenchymal stem cell (MSC) culture medium</td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;width:276px;">L-glutamine</td>
			<td style="width:259px;">Life Technologies</td>
			<td>25030-081</td>
			<td>Supplementation for MSC complete medium</td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;width:276px;">Penicillin/Streptomycin</td>
			<td style="width:259px;">Life Technologies</td>
			<td>15070-063</td>
			<td>Supplementation for PBMC/leukocyte and MSC complete medium</td>
		</tr>
		<tr height="80">
			<td height="80" style="height:80px;width:276px;">Fetal bovine serum (FBS)</td>
			<td style="width:259px;">1) Hyclone, for MSC culture&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2) Life Technologies, for all other cells (i.e. PBMCs, specific leukocyte populations)</td>
			<td style="width:121px;">1) SH30070.03M 2) 10091-148</td>
			<td>Pre-test lots for support of MSC in vitro culture</td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;width:276px;">24-well cell culture plate</td>
			<td style="width:259px;">Corning</td>
			<td>COR3524</td>
			<td>Co-culture plate</td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;width:276px;">50 mL centrifuge tube</td>
			<td style="width:259px;">Corning</td>
			<td style="width:121px;">430291</td>
			<td>Isolation PBMCs from whole blood by Ficoll-Paque PLUS</td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;width:276px;">15 mL centrifuge tube&#160;</td>
			<td style="width:259px;">Corning</td>
			<td style="width:121px;">430766</td>
			<td>Collection of the labeled and unlabeled cell fractions</td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Round-bottom tubes</td>
			<td style="width:259px;">BD Falcon&#160;</td>
			<td style="width:121px;">352008</td>
			<td>Collection of cells for flow cytometric analysis</td>
		</tr>
	</tbody>
</table>

assessment of the immunomodulatory properties of human mesenchymal stem cells (mscs)

The immunomodulatory properties of multilineage human mesenchymal stem cells (MSCs) appear to be highly relevant for clinical use towards a wide-range of immune-related diseases. Mechanisms involved are increasingly being elucidated and in this article, we describe the basic experiment to assess MSC immunomodulation by assaying for suppression of effector leukocyte proliferation. Representing activation, leukocyte proliferation can be assessed by a number of techniques, and we describe in this protocol the use of the fluorescent cellular dye carboxyfluorescein succinimidyl ester (CFSE) to label leukocytes with subsequent flow cytometric analyses. This technique can not only assess proliferation without radioactivity, but also the number of cell divisions that have occurred as well as allowing for identification of the specific population of proliferating cells and intracellular cytokine/factor expression. Moreover, the assay can be tailored to evaluate specific populations of effector leukocytes by magnetic bead surface marker selection of single peripheral blood mononuclear cell populations prior to co-culture with MSCs. The flexibility of this co-culture assay is useful for investigating cellular interactions between MSCs and leukocytes.

Figure 1 denotes the overall schema of the experiment, and Figure 2 demonstrates the appearance of the various cell culture conditions as visualized by phase-contrast inverted microscopy. MSCs are adherent cells with a fibroblastic, spindle-shaped morphology, whereas PBMCs and leukocytes are small round non-adherent cells. These two morphologically different cell types can be clearly seen in the co-culture. At the end of the assay, when the PBMCs (or leuckotyes) are aspirated for flow cytometric analyses, ev...

Watch this Scientific Journal Video about Assessment of the Immunomodulatory Properties of Human Mesenchymal Stem Cells MSCs at JoVE.com

Assessment of the Immunomodulatory Properties of Human Mesenchymal Stem Cells MSCs

The immunomodulatory properties of human mesenchymal stem cells (MSC) appear increasingly relevant for clinical application. Using a co-culture system of MSCs and peripheral blood leukocytes pre-stained with the fluorescent dye carboxyfluorescein succinimidyl ester (CFSE), we describe the in vitro assessment of MSC immunomodulation on effector leukocyte proliferation and specific subpopulations.

Assessment of the Immunomodulatory Properties of Human Mesenchymal Stem Cells (MSCs)

The immunomodulatory properties of multilineage human mesenchymal stem cells (MSCs) appear to be highly relevant for clinical use towards a wide-range of ...

assessment-immunomodulatory-properties-human-mesenchymal-stem-cells

Research

JoVE Journal

Immunology and Infection

12.1K Views.  National Health Research Institutes (NHRI). The immunomodulatory properties of human mesenchymal stem cells (MSC) appear increasingly relevant for clinical application. Using a co-culture system of MSCs and peripheral blood leukocytes pre-stained with the fluorescent dye carboxyfluorescein succinimidyl ester (CFSE), we describe the in vitro assessment of MSC immunomodulation on effector leukocyte proliferation and specific subpopulations.